Terns Pharma is due to release data from an early-stage trial of an obesity treatment in pill form in the second half. Positive data would send the stock higher.
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds
Read Next
- LiquidityBook completes SOC 1 Type 1 and SOC 2 Type 1 audits
- Harnessing AI for Neuroscience: IIT Madras and NVIDIA’s Innovative Approach
- International Criminal Court issues arrest warrants for Netanyahu and Hamas officials
- RBI purchases $9.6 billion in September to curb rupee’s appreciation amid Fed rate cut buzz, ET BFSI
- Asian Development Bank to provide $4.25 billion to Tata Power for clean energy power projects, ET BFSI
- SEC charges Touzi Capital in connection with $115M securities offering fraud
- NVIDIA Reports Record Q3 Revenue Amid AI Demand Surge